•  Live Chat
  •  1-800-399-VETS
  • Case Studies

    Gleostine (lomustine) FDA-Approved Human Drug Has Been Reported Useful for the Management of Malignant Tumors in Cats

    Lomustine (GleostineTM) has been reported to be an effective first- and second-line chemotherapy treatment for tumor-bearing cats. The optimal reported dosing schedule is 50–60 mg/m2 PO every six weeks. Lomustine-induced hepatoxicity in cats is minimal compared to that observed in dogs. Compounded lomustine capsules should not be used because recent findings indicate that many sources ...


    Gleostine (lomustine) FDA-Approved Human Drug Has Been Reported Useful for Managing Malignant Tumors in Dogs

    Lomustine (GleostineTM) has been reported to be an effective first- and second-line chemotherapy treatment for tumor-bearing dogs. The most frequently reported toxicoses have been delayed myelosuppression, in particular neutropenia, and an elevation in serum liver enzyme laboratory values. These toxicities were reversible with supportive therapy and lomustine treatment cessation ...

    News Bulletins

    Small but beautiful: NYR.com's penthouse is offered at just $748,000.NEW YORK, June 24, 2018 /PRNewswire/ -- Penthouses in New York are usually associated with very high price tags; the most expensive penthouse currently on the market in the city has an asking price of $180 million. However, leading New York Manhattan boutique brokerage New York...


    SMART Technologies Inc. (PRNewsfoto/SMART Technologies Inc.)SMART Technologies launches new research at ISTE 2018 including a personalized profile configurator for schools to assess individual EdTech capabilities CALGARY, Alberta and CHICAGO, June 24, 2018 /PRNewswire/ -- A new global study from SMART Technologies, the world leader in...


    Renova Therapeutics is a development-stage biotechnology company working to create transformational gene and peptide therapies that treat the most prevalent diseases to restore health and renew life. (PRNewsfoto/Renova Therapeutics)SAN DIEGO, June 24, 2018 /PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that an abstract of a study in a preclinical model of type 1 diabetes was accepted as a...


    Pulsus Logo (PRNewsfoto/PULSUS)Subscription based scholarly publishing journals and indexing sites are disappearing gradually, told Pulsus CEO, Dr Srinubabu. LONDON, June 24, 2018 /PRNewswire/ -- Open Access publishing is gaining popularity as the world is increasingly connected online today, facilitating...


    (PRNewsFoto/American Diabetes Association)ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- Adding the selective SGLT2 inhibitor dapagliflozin to intensive insulin therapy in adults with type 1 diabetes (T1D) who had sub-optimal glycemic control reduced blood glucose levels, aided in weight loss and led to a reduction in...


    Copyright © 2015 Amatheon Inc. All Rights Reserved. Privacy Policy |  Terms of Use | Store Policy
    livechat